Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti, Kurt Alex Schalper, Daniel E Carvajal et al. · Laboratory Investigation · 2013
Cited by 755 works. doi:10.1038/labinvest.2013.130
Authors
- Vamsidhar Velcheti
- Kurt Alex Schalper
- Daniel E Carvajal
- Valsamo Anagnostou
- Konstantinos Nikolaos Syrigos
- Mario Sznol
- Roy S. Herbst
- Scott N. Gettinger
- Lieping Chen
- David L. Rimm
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression